• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Morsy, E., Badrah, M., AbdElrahman, E., Galal, A. (2024). SERUM CHROMOGRANIN A AS EARLY BIOMARKER FOR DIAGNOSIS OF DIABETIC KIDNEY DISEASE IN TYPE 2 DIABETES MELLITUS. ALEXMED ePosters, 6(1), 7-8. doi: 10.21608/alexpo.2024.262845.1763
Eman Youssef Morsy; Mai Hesham Badrah; Eman Zakareya AbdElrahman; Asmaa Masoud Abd ElMageid Galal. "SERUM CHROMOGRANIN A AS EARLY BIOMARKER FOR DIAGNOSIS OF DIABETIC KIDNEY DISEASE IN TYPE 2 DIABETES MELLITUS". ALEXMED ePosters, 6, 1, 2024, 7-8. doi: 10.21608/alexpo.2024.262845.1763
Morsy, E., Badrah, M., AbdElrahman, E., Galal, A. (2024). 'SERUM CHROMOGRANIN A AS EARLY BIOMARKER FOR DIAGNOSIS OF DIABETIC KIDNEY DISEASE IN TYPE 2 DIABETES MELLITUS', ALEXMED ePosters, 6(1), pp. 7-8. doi: 10.21608/alexpo.2024.262845.1763
Morsy, E., Badrah, M., AbdElrahman, E., Galal, A. SERUM CHROMOGRANIN A AS EARLY BIOMARKER FOR DIAGNOSIS OF DIABETIC KIDNEY DISEASE IN TYPE 2 DIABETES MELLITUS. ALEXMED ePosters, 2024; 6(1): 7-8. doi: 10.21608/alexpo.2024.262845.1763

SERUM CHROMOGRANIN A AS EARLY BIOMARKER FOR DIAGNOSIS OF DIABETIC KIDNEY DISEASE IN TYPE 2 DIABETES MELLITUS

Article 1, Volume 6, Issue 1, January 2024, Page 7-8  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2024.262845.1763
View on SCiNiTO View on SCiNiTO
Authors
Eman Youssef Morsy1; Mai Hesham Badrah2; Eman Zakareya AbdElrahman3; Asmaa Masoud Abd ElMageid Galal email 4
1Department of Internal Medicine, Faculty of Medicine, University of Alexandria
2Department of Internal Medicine Faculty of Medicine Alexandria University
3Department of Clinical and Chemical Pathology, Faculty of Medicine Alexandria University
4Department of Internal Medicine, Faculty of Medicine, Alexandria University
Abstract
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Poorly controlled diabetes lead to serious complications, including retinopathy; nephropathy; peripheral neuropathy, atherosclerotic cardiovascular, peripheral arterial and cerebrovascular disease.
Diabetic kidney disease (DKD) is one of the most prominent complications of diabetes and is the leading cause of end-stage renal disease, requiring costly renal replacement therapy(dialysis or transplantation).
DKD is a clinical syndrome characterized by: persistent albuminuria (albumin to creatine ratio [ACR] >30 mg/g ) and/ or progressive reduction in the glomerular filtration rate (eGFR< 60 mL/min/1.73 m2)
Chromogranin A (CgA) is the main member of the chromogranin glycoprotein family and is an acidic hydrophilic glycoprotein.The kidney is the main organ for the removal of CgA, and it is elevated in serum with declining renal function. In patients with renal failure, serum CgA increases higher than creatinine and other biomarkers.
Keywords
Diabetic kidney disease (DKD); Chromogranin A (CgA); TYPE 2 DIABETES MELLITUS
Supplementary Files
download 1763 22 (19).pdf
Statistics
Article View: 142
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.